New drug approvals for 2022: Synthesis and clinical applications

• Published in: Medicinal research reviews Vol. 43; no. 6; pp. 2352 - 2391
• Main Authors: Yuan, Shuo, Shen, Dan‐Dan, Jia, Rui, Sun, Ju‐Shan, Song, Jian, Liu, Hong‐Min
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2023
• Subjects: Chemical synthesis; Drug development; Drugs; FDA approval; Radiation therapy; chemical synthesis; mechanism of action; fragment-based drug discovery; clinical applications; new drugs
• ISSN: 0198-6325; 1098-1128; 1098-1128
• DOI: 10.1002/med.21976

The U.S. Food and Drug Administration has approved a total of 37 new drugs in 2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 chemical entities, including 17 small molecule drugs, 1 radiotherapy, and 2 diagnostic agents, provide privileged scaffolds, breakthrough clinical benefits, and a new mechanism of action for the discovery of more potent clinical candidates. The structure‐based drug development with clear targets and fragment‐based drug development with privileged scaffolds have always been the important modules in the field of drug discovery, which could easily bypass the patent protection and bring about improved biological activity. Therefore, we summarized the relevant valuable information about clinical application, mechanism of action, and chemical synthesis of 17 newly approved small molecule drugs in 2022. We hope this timely and comprehensive review could bring about creative and elegant inspiration on the synthetic methodologies and mechanism of action for the discovery of new drugs with novel chemical scaffolds and extended clinical indications.